Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President of Medical Affairs to Advance Novel Serotonergic Agonist Pipeline

Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists, announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, effective immediately. Kramer brings more than 20 years of neuroscience-focused medical affairs leadership, including roles at Bristol Myers Squibb, Karuna Therapeutics and AbbVie, and is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.

The company is developing proprietary novel serotonergic agonists, synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. Helus Pharma aims to improve the treatment landscape through the introduction of these agonists that aim to provide durable improvements in mental health.

Helus Pharma is currently developing HLP003, a proprietary novel serotonergic agonist in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also developing HLP004, another proprietary novel serotonergic agonist in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational novel serotonergic agonists.

The appointment of Dr. Kramer represents a strategic move for Helus Pharma as the company advances its clinical programs. With his extensive experience at major pharmaceutical companies including Bristol Myers Squibb, Karuna Therapeutics and AbbVie, Kramer brings valuable expertise in medical affairs leadership specifically focused on neuroscience. This expertise is particularly relevant given Helus Pharma's focus on developing treatments for mental health conditions through novel serotonergic agonists.

For company updates and to learn more about Helus Pharma, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP. To view the full press release, visit https://ibn.fm/FdEXH.